Defunct Company
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
693
NCT01968460
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
Phase: Phase 2/3
Role: Lead Sponsor
Start: Dec 31, 2013
Completion: Jun 30, 2015
NCT03329508
A Phase 3 Study With P2B001 in Subjects With Early Parkinson's
Phase: Phase 3
Start: Jan 19, 2018
Completion: Oct 31, 2021